ALKERMES | ALKS - Market Capitalization


ALKERMES reported $5.16B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 391.49B 12.34B Feb/2026
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
ALKERMES USD 5.65B 696M Feb/2026
Amgen USD 201.45B 25.2B Feb/2026
Biogen USD 27.01B 1.19B Feb/2026
BioMarin Pharmaceutical USD 11.99B 575M Feb/2026
Bristol-Myers Squibb USD 123.58B 13.77B Feb/2026
Coherus Biosciences USD 278M 184M Jun/2025
Eli Lilly USD 1.01T 3.37B Feb/2026
Gilead Sciences USD 183.59B 31.31B Feb/2026
Heron Therapeutics USD 145M 6M Sep/2023
Ionis Pharmaceuticals USD 10.43B 4.14B Sep/2025
J&J USD 500.24B 67.44B Dec/2025
Malin Corporation EUR 150.45M 12.13M Jan/2026
Merck USD 300.37B 39.11B Feb/2026
Minerva Neurosciences USD 43M 5M Dec/2023
Nektar Therapeutics USD 113M 4M Sep/2023
Neurocrine Biosciences USD 13.68B 465M Feb/2026
Otsuka Holdings JPY 5.69T 867.19B Feb/2026
Ovoca Bio EUR 7.54M 4.28M Jun/2022
Pfizer USD 152.89B 11.32B Feb/2026
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Vertex Pharmaceuticals USD 120.12B 5.09B Feb/2026